FDA Approved • Melanocortin Agonist

PT-141: Bremelanotide for Sexual Dysfunction

By MeetPeptide Research Team

Last updated: March 2026

PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved as Vyleesi in June 2019. Unlike PDE5 inhibitors that target blood flow, PT-141 acts centrally on the hypothalamus to modulate sexual desire through the melanocortin pathway.

0
FDA Approved
(Vyleesi)
MC4R
Primary
Receptor Target
0
Approved
SC Dose
Background

What Is PT-141?

Originally derived from the tanning peptide Melanotan II, PT-141 was discovered when researchers noticed sexual arousal as a side effect. It's the first and only FDA-approved treatment that works on central desire pathways rather than peripheral blood flow.

🧠
MC4R Activation

Activates melanocortin-4 receptors in the hypothalamus, modulating dopaminergic and oxytocinergic pathways involved in sexual desire and arousal.

⚡
Central Mechanism

Unlike Viagra/Cialis which act on penile blood flow, PT-141 works in the brain on desire pathways. This makes it effective for desire disorders, not just performance.

🔬
Derived from MT-II

A cyclic heptapeptide analog of alpha-MSH, structurally modified from Melanotan II to reduce melanogenic activity while retaining melanocortin receptor selectivity.

💉
Subcutaneous Delivery

Administered via autoinjector 45 minutes before anticipated activity. The nasal spray formulation was abandoned after blood pressure concerns in early trials.

Research

What the Research Shows

📋

Context: PT-141 has robust Phase III clinical trial data supporting its FDA approval. The RECONNECT trials enrolled over 1,200 premenopausal women with HSDD and demonstrated statistically significant improvement in desire and distress scores.

RECONNECT Phase III — HSDD in Women (n=1,247)
Significant increase in desire score and decrease in distress vs placebo over 24 weeks
Positive
Male Erectile Dysfunction — Phase II
Improved erection quality in men with ED who failed PDE5 inhibitors
Positive
Satisfying Sexual Events (SSE)
Statistically significant increase in SSEs per month vs placebo
Positive
Safety

Side Effects & Safety Profile

Nausea
Most common side effect — ~40% of patients, usually decreases with repeat use
40%
Flushing
Facial flushing reported in clinical trials
20%
Headache
Transient headache, typically resolves within hours
11%
Blood Pressure Increase
Transient small increases; contraindicated in uncontrolled hypertension
Transient
Sources

Study Citations

Phase III
RECONNECT: Bremelanotide for Hypoactive Sexual Desire Disorder — Randomized, Double-Blind, Placebo-Controlled Trial
Kingsberg SA, et al. · Obstetrics & Gynecology, 2019
FDA Label
VYLEESI (bremelanotide injection) — Full Prescribing Information
FDA/AMAG Pharmaceuticals · Approved June 21, 2019 · NDA 210557
Review
Bremelanotide: First Approval
Dhillon S, Keam SJ. · Drugs, 2019;79(14):1599-1606

Self-Assessment

Who Researches PT-141?

This Research Is Commonly Explored By People Who...

  • Are interested in melanocortin receptor pharmacology and central desire pathways
  • Want to understand the first FDA-approved centrally-acting sexual desire treatment
  • Are researching alternatives to PDE5 inhibitors for sexual dysfunction
  • Are exploring the broader melanocortin system and its therapeutic potential

This Research May Not Be Relevant If...

  • You're looking for something without nausea risk — 40% incidence is substantial
  • You have uncontrolled hypertension or cardiovascular concerns
  • You want a daily-use medication — PT-141 is on-demand, max 8 doses/month
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
⚕️ Disclaimer: This is educational content, not medical advice. Always consult a healthcare provider before making decisions about your health.
Bottom Line

Key Takeaways

✅ What We Know
  • FDA-approved June 2019 for HSDD (Vyleesi)
  • Works centrally via MC4R — unique mechanism
  • Phase III trials showed significant efficacy
  • 1.75mg SC injection, on-demand use
  • Also studied for male ED with positive Phase II results
⚠️ What We Don't Know
  • 40% nausea rate is the main tolerability concern
  • Not approved for men (only women with HSDD)
  • Long-term effects of chronic melanocortin activation
  • Can cause skin hyperpigmentation with repeated use
  • Contraindicated in uncontrolled hypertension

🔬 Verified Research Source

Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.

🧬 PT-141 (Bremelanotide) Buy from Swiss Chems — Lab-tested, verified purity → Shop Now

Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.

Related Resources

☀️
Melanotan II Guide
Parent compound of PT-141
→ 💕
Kisspeptin Guide
Reproductive peptide
→ ⚡
Testagen Guide
Testicular bioregulator
→ 🩹
BPC-157 Guide
Healing peptide research
→
⚠️ Disclaimer

PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women only. Off-label use is not endorsed. This page is for educational purposes only. Not medical advice. FDA Approved (Women HSDD) Off-Label Uses Research Only